The current and future role of biomarkers in type 2 cytokine-mediated asthma management.

摘要: Assessment and management of asthma is complicated by the heterogeneous pathophysiological mechanisms that underlie its clinical presentation, which are not necessarily reflected in standardized paradigms necessitate an individualized approach to treatment. This particularly important with emerging availability a variety targeted forms therapy may only be appropriate for use particular patient subgroups. The identification biomarkers can potentially aid diagnosis inform prognosis, help guide treatment decisions allow clinicians predict monitor response Biomarkers have been identified from sources, including airway, exhaled breath blood. include fractional nitric oxide, measurement identify patients most likely benefit inhaled corticosteroids anti-immunoglobulin E therapy. measured blood relatively non-invasive technically more straightforward than those or directly airway. well established these eosinophil count serum periostin, both demonstrated utility identifying anti-interleukin therapies, monitoring subsequent response. For example, periostin appears biomarker responsiveness corticosteroid as suitable candidates anti-IL-13 therefore avoid unnecessary morbidity high-dose cost-effective therapies. Ongoing trials helping further elucidate role routine practice, range other circulating novel potential currently being investigated research setting.